ORIC Pharmaceuticals Presents Positive Enozertinib Data for NSCLC Patients with EGFR Atypical Mutations at ESMO Asia Congress 2025.

ORIC Pharmaceuticals presented data on enozertinib, a treatment for non-small cell lung cancer (NSCLC) with EGFR atypical mutations, at the ESMO Asia Congress 2025. The trial showed promising results, including an 80% overall response rate and 100% intracranial response rate in first-line patients. Enozertinib also demonstrated a competitive safety profile with manageable on-target toxicity. Enrollment and follow-up continue, with the next update expected mid-2026 ahead of potential Phase 3 trial initiation.